Cadila Healthcare Limited Roxithromycin Export Data — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Roxithromycin Export Records India — #9 Exporter, 13 Shipments, $51.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Roxithromycin

India Pharmaceutical Trade Intelligence

$4.2M78 Suppliers30 CountriesHS 30049099

ExportsIndia → VIETNAM33.9%India → CAMBODIA18.3%

ImportsGERMANY → India$752

#1 Supplier: BRAWN LABORATORIES

Cadila Healthcare Limited — Roxithromycin Exporter #9 | $51.2K Trade Value | TransData Nexus | TransData Nexus

Cadila Healthcare Limited — Roxithromycin Exporter Profile

Indian Pharmaceutical Exporter · #9 for Roxithromycin · $51.2K export value · DGFT Verified

Cadila Healthcare Limited is the #9 Indian exporter of Roxithromycin with $51.2K in export value and 13 verified shipments. Cadila Healthcare Limited holds a 1.2% market share in Roxithromycin exports across 1 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

Cadila Healthcare Limited — Roxithromycin Export Profile: Buyers & Destinations

Cadila Healthcare Limited Roxithromycin export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Roxithromycin?

Country	Value	Shipments	Share
VIETNAM	$900.0K	18	24.8%
CAMBODIA	$763.2K	68	21.0%
AUSTRALIA	$758.8K	54	20.9%
NEW ZEALAND	$405.4K	10

Who Are the Top Buyers of Roxithromycin from India?

Buyer	Country	Value	Orders
TEVA PHARMA (NEW ZEALAND) LIMITED	NEW ZEALAND	$235.2K	5
MILITARY COMMERICAL JOINT STOCK BANK	VIETNAM	$200.0K	4
APOTEX PTY LTD.,	AUSTRALIA	$182.5K	11
TEVA PHARMA NEW ZEALAND LIMITED	NEW ZEALAND	$170.2K	5
ISKP PHARMA CO., LTD	CAMBODIA	$164.8K	4
HEUMANN PHARMA GMBH CO. GENERICA KG	GERMANY	$159.7K	10
ARROW PHARMACEUTICALS PTY LTD,	AUSTRALIA	$150.2K	10
OPHAM - ROUTE DIGUE ANDRANOAMBO	MADAGASCAR	$129.0K	8
ARROW PHARMACEUTICALS PTY LTD.,	AUSTRALIA	$112.2K	7
CAMEL INTERNATIONAL IM-EXPORT	VIETNAM	$93.2K	3

India's Roxithromycin is purchased by 125 buyers worldwide. The top buyer is TEVA PHARMA (NEW ZEALAND) LIMITED (NEW ZEALAND), followed by MILITARY COMMERICAL JOINT STOCK BANK and APOTEX PTY LTD.,.

How Does Cadila Healthcare Limited Compare to Nearest Roxithromycin Exporters?

Exporters ranked immediately above and below #9 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
7	UMEDICA LABORATORIES PRIVATE LIMITED	$93.2K	3	1	$31.1K
8	MERCURY LABORATORIES LIMITED	$73.2K	5	3	$14.6K
9	CADILA HEALTHCARE LIMITED ★	$51.2K	13	1	$3.9K
10	THEON PHARMACEUTICALS LIMITED	$46.9K	3	1	$15.6K
11	PANGENE BIOTECH LTD	$44.0K	4	1	$11.0K

Cadila Healthcare Limited ranks #9 among 78 Indian Roxithromycin exporters. Average shipment value of $3.9K compared to the market average of $36.7K. The closest competitors by value are UMEDICA LABORATORIES PRIVATE LIMITED and MERCURY LABORATORIES LIMITED.

Which Indian Ports Ship Roxithromycin Exports?

Port	Shipments	% Share
DELHI AIR CARGO ACC (INDEL4)	64	15.0%
SAHAR AIR CARGO ACC (INBOM4)	40	9.4%
SAHAR AIR	35	8.2%
Bombay Air	29	6.8%
NHAVA SHEVA SEA (INNSA1)	25	5.9%
DELHI AIR	24	5.6%
TUGLAKABAD ICD	14	3.3%
BANGALORE ICD	14	3.3%

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Roxithromycin Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)

Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.

In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.

The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Roxithromycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 30+ countries, 125+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Roxithromycin

Roxithromycin

Cadila Healthcare Limited — Roxithromycin Exporter Profile

Cadila Healthcare Limited — Roxithromycin Export Profile: Buyers & Destinations

Where Does India Export Roxithromycin?

Who Are the Top Buyers of Roxithromycin from India?

What Is India's Total Roxithromycin Export Value and How Much Does Cadila Healthcare Limited Contribute?

What Is the Average Shipment Value for Cadila Healthcare Limited's Roxithromycin Exports?

How Does Cadila Healthcare Limited Compare to Other Indian Roxithromycin Exporters?

Regulatory Requirements: Exporting Roxithromycin to Key Markets

Australia — TGA

How Does Cadila Healthcare Limited Compare to Nearest Roxithromycin Exporters?

Which Indian Ports Ship Roxithromycin Exports?

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Roxithromycin Exports

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

About Cadila Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Roxithromycin Export Data from Cadila Healthcare Limited

Roxithromycin Stats

Company Overview

Top Products by Cadila Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source